Kamada Receives FDA Approval for Houston Plasma Collection Center

Kamada announces FDA approval for its plasma collection center in Houston, Texas. The 12,000 sq ft facility can support 50 donor beds and has a planned capacity of approximately 50,000 liters per year. The approval was obtained after an on-site inspection by the FDA during Q2. The center is now cleared to commence commercial sales of normal source plasma.

Kamada Ltd. (NASDAQ: KMDA) has received FDA approval for its plasma collection center in Houston, Texas, allowing commercial sales of normal source plasma. The 12,000 square foot facility features 50 donor beds with an annual collection capacity of 50,000 liters of plasma [1]. The Houston center, positioned to be one of the largest specialty plasma collection sites in the U.S., is expected to generate $8-10 million in annual revenue at full capacity [1].

The facility will collect both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D. This marks Kamada's third Texas-based site, alongside locations in San Antonio and Beaumont. The FDA approval of Kamada's Houston plasma center unlocks $8-10M annual revenue potential and strengthens specialty plasma collection capabilities [2].

The approval follows an FDA inspection conducted in Q2 2025 and represents the third Texas-based plasma collection site in Kamada's growing network. The strategic importance of this approval extends beyond immediate revenue potential. By establishing what's anticipated to be one of the largest specialty plasma collection centers in the U.S., Kamada is securing a critical supply chain component for its plasma-derived therapeutics business [2].

The company's focus on specialty plasma varieties (Anti-Rabies, Anti-D) targets higher-margin products compared to standard plasma, potentially improving overall profit margins. Kamada's pursuit of subsequent EMA approval for this facility indicates plans to leverage these plasma resources for global markets [2].

The multi-regulatory approach aligns with industry best practices for maximizing return on infrastructure investments while ensuring compliance with international standards for biological products [2].

References:
[1] https://www.kamada.com/news/kamada-announces-fda-approval-of-its-plasma-collection-center-in-houston-texas/
[2] https://www.stocktitan.net/news/KMDA/kamada-announces-fda-approval-of-its-plasma-collection-center-in-28n0ac7purnl.html